VRDN Q2 2021 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+548.8% YoY

Gross Profit

-$11M-1052.8% margin

Operating Income

-$18M-1651.2% margin

Net Income

-$18M-1648.1% margin

EPS (Diluted)

$-2.22

QoQ Revenue Growth

-24.9%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$118M

Total Liabilities

$19M

Stockholders' Equity

$99M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$168,000	+548.8%
Gross Profit	-$11M	$168,000	-6930.4%
Operating Income	-$18M	-$6M	-182.4%
Net Income	-$18M	-$6M	-179.2%

Revenue Segments

Collaboration Revenue, Related Party

$1M100%